Close collaboration between the different teams might lead to a high chance of success, and the antibodies generated for the treatment of one type of tumor can also be used for the screening of other types since, as shown in the HER2 example, breast tumors that do not belong to this subtype or tumors from other types can also be positive for its expression and could be treated with trastuzumab. This evidence concerns the gene ERBB2 and neoplasm.